Jennifer W Evans1, Joanna Szczepanik2, Nancy Brutsché2, Lawrence T Park2, Allison C Nugent2, Carlos A Zarate2. 1. Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland. Electronic address: jennifer.evans@nih.gov. 2. Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.
Abstract
BACKGROUND: The symptoms of major depressive disorder (MDD) are rapidly alleviated by administration of a single dose of the glutamatergic modulator ketamine. However, few studies have investigated the potential sustained neural effects of this agent beyond immediate infusion. This study used functional magnetic resonance imaging to examine the effect of a single ketamine infusion on the resting state default mode network (DMN) at 2 and 10 days after a single ketamine infusion in unmedicated subjects with MDD as well as healthy control subjects (HCs). METHODS: Data were drawn from a double-blind, placebo-controlled crossover study of 58 participants (33 with MDD and 25 HCs) who received an intravenous infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 separate test days spaced 2 weeks apart. Eight minutes of functional magnetic resonance imaging resting state data was acquired at baseline and at about 2 and 10 days after both infusions. The DMN was defined using seed-based correlation and was compared across groups and scans. RESULTS: In subjects with MDD, connectivity between the insula and the DMN was normalized compared with HCs 2 days postketamine infusion. This change was reversed after 10 days and did not appear in either of the placebo scans. Group-specific connectivity differences in drug response were observed, most notably in the insula in subjects with MDD and in the thalamus in HCs. CONCLUSIONS: Connectivity changes in the insula in subjects with MDD suggest that ketamine may normalize the interaction between the DMN and salience networks, supporting the triple network dysfunction model of MDD. Published by Elsevier Inc.
RCT Entities:
BACKGROUND: The symptoms of major depressive disorder (MDD) are rapidly alleviated by administration of a single dose of the glutamatergic modulator ketamine. However, few studies have investigated the potential sustained neural effects of this agent beyond immediate infusion. This study used functional magnetic resonance imaging to examine the effect of a single ketamine infusion on the resting state default mode network (DMN) at 2 and 10 days after a single ketamine infusion in unmedicated subjects with MDD as well as healthy control subjects (HCs). METHODS: Data were drawn from a double-blind, placebo-controlled crossover study of 58 participants (33 with MDD and 25 HCs) who received an intravenous infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 separate test days spaced 2 weeks apart. Eight minutes of functional magnetic resonance imaging resting state data was acquired at baseline and at about 2 and 10 days after both infusions. The DMN was defined using seed-based correlation and was compared across groups and scans. RESULTS: In subjects with MDD, connectivity between the insula and the DMN was normalized compared with HCs 2 days postketamine infusion. This change was reversed after 10 days and did not appear in either of the placebo scans. Group-specific connectivity differences in drug response were observed, most notably in the insula in subjects with MDD and in the thalamus in HCs. CONCLUSIONS: Connectivity changes in the insula in subjects with MDD suggest that ketamine may normalize the interaction between the DMN and salience networks, supporting the triple network dysfunction model of MDD. Published by Elsevier Inc.
Entities:
Keywords:
Default mode network; Functional magnetic resonance imaging (fMRI); Glutamatergic modulator; Ketamine; Major depressive disorder; Resting state
Authors: Michael D Greicius; Benjamin H Flores; Vinod Menon; Gary H Glover; Hugh B Solvason; Heather Kenna; Allan L Reiss; Alan F Schatzberg Journal: Biol Psychiatry Date: 2007-01-08 Impact factor: 13.382
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters Journal: Arch Gen Psychiatry Date: 2005-06
Authors: O M Doyle; S De Simoni; A J Schwarz; C Brittain; O G O'Daly; S C R Williams; M A Mehta Journal: J Pharmacol Exp Ther Date: 2013-01-31 Impact factor: 4.030
Authors: S De Simoni; A J Schwarz; O G O'Daly; A F Marquand; C Brittain; C Gonzales; S Stephenson; S C R Williams; M A Mehta Journal: Neuroimage Date: 2012-09-23 Impact factor: 6.556
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: J W Murrough; K A Collins; J Fields; K E DeWilde; M L Phillips; S J Mathew; E Wong; C Y Tang; D S Charney; D V Iosifescu Journal: Transl Psychiatry Date: 2015-02-17 Impact factor: 6.222
Authors: Milan Scheidegger; Martin Walter; Mick Lehmann; Coraline Metzger; Simone Grimm; Heinz Boeker; Peter Boesiger; Anke Henning; Erich Seifritz Journal: PLoS One Date: 2012-09-24 Impact factor: 3.240
Authors: N R Driesen; G McCarthy; Z Bhagwagar; M Bloch; V Calhoun; D C D'Souza; R Gueorguieva; G He; R Ramachandran; R F Suckow; A Anticevic; P T Morgan; J H Krystal Journal: Mol Psychiatry Date: 2013-01-22 Impact factor: 15.992
Authors: Allison C Nugent; Cristan Farmer; Jennifer W Evans; Sam L Snider; Dipavo Banerjee; Carlos A Zarate Journal: Hum Brain Mapp Date: 2019-06-09 Impact factor: 5.038
Authors: Jessica L Reed; Allison C Nugent; Maura L Furey; Joanna E Szczepanik; Jennifer W Evans; Carlos A Zarate Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2019-01-25
Authors: Meng Li; Marie Woelfer; Lejla Colic; Adam Safron; Catie Chang; Hans-Jochen Heinze; Oliver Speck; Helen S Mayberg; Bharat B Biswal; Giacomo Salvadore; Anna Fejtova; Martin Walter Journal: Eur Arch Psychiatry Clin Neurosci Date: 2018-10-23 Impact factor: 5.270
Authors: Christoph Kraus; Anahit Mkrtchian; Bashkim Kadriu; Allison C Nugent; Carlos A Zarate; Jennifer W Evans Journal: Neuropsychopharmacology Date: 2020-01-29 Impact factor: 7.853
Authors: Bashkim Kadriu; Maximillian Greenwald; Ioline D Henter; Jessica R Gilbert; Christoph Kraus; Lawrence T Park; Carlos A Zarate Journal: Int J Neuropsychopharmacol Date: 2021-01-20 Impact factor: 5.176